Phase I Trial of Fludarabine, Bortezomib and Rituximab for Relapsed and Refractory Indolent and Mantle Cell Non-Hodgkin Lymphoma

Based on the hypothesis that bortezomib may potentiate fludarabine activity by inhibiting DNA repair, we designed a phase I trial using this combination with rituximab in patients with relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma. Twenty-four patients were enrolled. Non-Hodg...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Barr, Paul M., Fu, Pingfu, Lazarus, Hillard M., Horvath, Nancy, Gerson, Stanton L., Koc, Omer N., Bahlis, Nizar J., Snell, Michael R., Dowlati, Afshin, Cooper, Brenda W.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2009
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2827854/
https://ncbi.nlm.nih.gov/pubmed/19656151
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2009.07836.x
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky